F. Dorigotti

发表

Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.

G. Franceschini, G. Gianfranceschi, C. Sirtori, 1995, Atherosclerosis.

Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF

P. Ponikowski, G. Rosano, Antonio Ramírez de Arellano, 2021, European journal of heart failure.

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

I. Piña, G. Filippatos, T. Friede, 2021, European journal of heart failure.

Responder analysis for improvement in 6‐min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency

P. Ponikowski, I. Piña, G. Filippatos, 2022, European journal of heart failure.

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency

P. Ponikowski, I. Piña, G. Filippatos, 2022, European journal of heart failure.

Minimal Clinically Important Difference for Six-minute Walk Test in Patients with HFrEF and Iron Deficiency.

I. Piña, G. Filippatos, T. Friede, 2022, Journal of cardiac failure.

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial

I. Piña, A. Cohen-Solal, G. Filippatos, 2022, European heart journal.

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial

G. Filippatos, M. Metra, J. Butler, 2022, European journal of heart failure.

Iron‐ovotransferrin preparation does not interfere with ciprofloxacin absorption

C. Sirtori, D. Baldassarre, N. Colombo, 1996, Clinical pharmacology and therapeutics.

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

P. Ponikowski, B. Lewis, A. Cohen-Solal, 2011, European heart journal.

Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study.

A. Coats, G. Rosano, P. McEwan, 2022, Journal of medical economics.

Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation

A. Cohen-Solal, L. Lund, P. McEwan, 2023, European journal of heart failure.